Subscribe to MDT Magazine News

Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference

March 8, 2011 9:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 8, 2011 /- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Roth 23rd Annual OC Growth Stock Conference in Laguna Niguel, CA.   The live...


Healthways announces new management changes

March 8, 2011 8:45 am | by The Associated Press | Comments

Healthways' CEO will again have the title of president at the wellness-program operator, while Stefen Brueckner, who has been president and chief operating officer for more than two years, will move in to an advisory position in April.Ben Leedle Jr. 50, has been the CEO of Healthways since...

Roundworm could provide new treatment for sepsis

March 8, 2011 8:35 am | by EurekAlert | Comments

(University of Liverpool) Research by the University of Liverpool has found that systemic inflammation caused by sepsis can be suppressed by a protein which occurs naturally in a type of roundworm.


The safety of daily magnesium oxide treatment for children with chronic constipation

March 8, 2011 7:36 am | by EurekAlert | Comments

(World Journal of Gastroenterology) A research team from Japan determined serum magnesium concentration in children with functional constipation treated with daily magnesium oxide. The results showed that serum magnesium concentration increased significantly, but not critically,...

Patient Satisfaction and Patient Education Increase When Hospitals Offer Interactive Technology

March 8, 2011 7:35 am | by Bio-Medicine.Org | Comments

DALLAS, March 8, 2011 /- Hospitals using interactive technology to communicate with patients increased patient satisfaction scores by approximately 10% and increased satisfaction with hospital educational materials and courses by as much as 42%, according to a white paper released by The...


K-V Pharmaceutical Company Announces Comprehensive Patient Assistance Program for Makenaâ„¢

March 8, 2011 7:34 am | by Bio-Medicine.Org | Comments

ST. LOUIS, March 8, 2011 /- K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a specialty pharmaceutical company, along with its branded subsidiary, Ther-Rx Corporation, today announced the details of its patient assistance program for Makena ™ -eligible patients....

13 Novel Genetic Components of Coronary Artery Disease Identified

March 8, 2011 6:34 am | by University Of Pennsylvania | Comments

An international analysis of 14 genome-wide association studies involving over 100,000 patients has identified 13 new genetic risk factors for coronary artery disease (CAD). Muredach P. Reilly, MBBCH, MSCE, associate professor of Medicine, University of Pennsylvania School of Medicine,...


CareFusion Launches Compact Ventilator to Enhance Home-Based Patient Mobility

March 8, 2011 6:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 8, 2011 /- CareFusion (NYSE: CFN ), a leading, global medical device company, today introduced a portable ventilator for adults and children who require mechanical ventilation at home. (Photo: ) The CareFusion...


CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires

March 8, 2011 6:33 am | by Bio-Medicine.Org | Comments

MISSISSAUGA, Ontario, March 8, 2011 /- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH ) announced today that it is making available to its common stockholders and Series 2 Class B common stockholders a "Stockholder Questionnaire," which the Company hopes will assist it in obtaining...


Kaletra (lopinavir/ritonavir): Label Change - Serious Health Problems in Premature Babies

March 8, 2011 6:30 am | by U.S. Food & Drug Administration | Comments

New Warning about serious heart, kidney, or breathing problems which can be fatal.

Amicus will resume studies on Pompe therapy

March 8, 2011 5:45 am | by The Associated Press | Comments

Amicus Therapeutics will resume studies on a treatment for the genetic disorder Pompe disease in the next few months, the company said Tuesday.The company said the Food and Drug Administration removed a clinical hold on testing of the therapy, and Amicus and regulators reached an agreement on...

Genzyme CEO Termeer may net $200M payout

March 8, 2011 4:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Genzyme Corp. CEO Henri Termeer could get more than $200 million from the sale of his company to French drugmaker Sanofi-aventis SA, according to a U.S. regulatory filing on Monday.

Heraeus to Launch Venus® Bulk Fill Syringes

March 8, 2011 4:35 am | by Bio-Medicine.Org | Comments

SOUTH BEND, Ind., March 8, 2011 /- Heraeus Kulzer, LLC, the leader in advancing dental esthetics and overall dental wellbeing, announced today that as a member of the Venus brand of low stress composites, Venus® Bulk Fill will now be available in syringes this March. The precise...

Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11

March 8, 2011 4:35 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 8, 2011 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today announced it will report fourth quarter and full year 2010 financial results before the NASDAQ Global Select Market opens on Friday, March 11, 2011. That same morning, Jack Lief, Arena's President and Chief...


Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test

March 8, 2011 4:34 am | by Bio-Medicine.Org | Comments

AUSTIN, Texas, March 8, 2011 /- (Nasdaq: VRML ) –Vermillion, a molecular diagnostics company, today announced the presentation of positive preliminary data from its collaboration with Johns Hopkins University School of Medicine to identify biomarkers that improve on the specificity...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.